| First Author | Meyer N | Year | 2023 |
| Journal | Cancers (Basel) | Volume | 15 |
| Issue | 17 | PubMed ID | 37686555 |
| Mgi Jnum | J:340450 | Mgi Id | MGI:7526922 |
| Doi | 10.3390/cancers15174278 | Citation | Meyer N, et al. (2023) Mast Cells Retard Tumor Growth in Ovarian Cancer: Insights from a Mouse Model. Cancers (Basel) 15(17) |
| abstractText | Ovarian cancer has the highest mortality rate among female reproductive tract malignancies. A complex network, including the interaction between tumor and immune cells, regulates the tumor microenvironment, survival, and growth. The role of mast cells (MCs) in ovarian tumor pathophysiology is poorly understood. We aimed to understand the effect of MCs on tumor cell migration and growth using in vitro and in vivo approaches. Wound healing assays using human tumor cell lines (SK-OV-3, OVCAR-3) and human MCs (HMC-1) were conducted. Murine ID8 tumor cells were injected into C57BL6/J wildtype (WT) and MC-deficient C57BL/6-Kit(W-sh/W-sh) (Kit(W-sh)) mice. Reconstitution of Kit(W-sh) was performed by the transfer of WT bone marrow-derived MCs (BMMCs). Tumor development was recorded by high-frequency ultrasonography. In vitro, we observed a diminished migration of human ovarian tumor cells upon direct or indirect MC contact. In vivo, application of ID8 cells into Kit(W-sh) mice resulted in significantly increased tumor growth compared to C57BL6/J mice. Injection of BMMCs into Kit(W-sh) mice reconstituted MCs and restored tumor growth. Our data show that MCs have a suppressive effect on ovarian tumor growth and may serve as a new therapeutic target. |
